Please Wait...

Mark W. Tengowski

Translation skills

Main profile

Mark W. Tengowski, DVM, MS, PhD
Mark W. Tengowski, DVM, MS, PhD
Scientific Director, MSK & More Medical Affairs

Dr. Tengowski brings a large breadth of applied medical knowledge, critical thinking ability, and drug development experience from compound nomination through post-marketing investigations to Bioclinica. In the industry since 1999, his imaging experience spans ultrastructural- and light-level microscopic evaluations to non-invasive imaging methods, applying imaging endpoints to nominate and advance compounds, manage safety findings, and achieve regulatory approval. Mark served as a medical advisor to the Business Development team, supporting new requests for clinical trials and consultation while being a scientific expert for projects with an inflammation or musculoskeletal focus (e.g., osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, NAFLD/NASH and cholangitis, Crohn's disease, ulcerative colitis, deep vein thrombosis, women's health [breast volume/density, vaginal dryness, uterine fibroids, and endometrial thickness], medical devices, and orphan diseases [hyperoxaluria, acid sphingomyelinase deficiency, Pompe disease, Gaucher disease, Niemann-Pick disease]). With a veterinary background in inflammation and pharmacology, Mark approaches protocols from a mechanistic point of view – devising an imaging strategy that will achieve the study's objective and end points. In the external environment, Mark has been an invited speaker to the FDA and been the author of draft guidance issuances, given posters and podium presentations at national and international meetings, participated in several disease workshops, and published numerous abstracts, articles, and book chapters. Dr. Tengowski is a graduate of the University of Wisconsin-Madison and is licensed to practice veterinary medicine in WI and NY states, with USDA-accreditation, and a member of the American College of Rheumatology.

Authored Publications

Mark Tengowski, DVM, PhD, Scientific Director, Bioclinica; Thomas Fuerst, PhD, Chief Science Officer, Bioclinica, and Claude B Sirlin, UC San Diego Medical Center and UC San Diego Liver Imaging Group. Magnetic resonance imaging fatty liver changes following surgical, lifestyle or drug treatments in obese, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis subjects. Journal of Imaging Medicine, September 2017.

Blogs

Medical Imaging of Non-Alcoholic Fatty Liver Diseases in Clinical Trials

The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), both potentially progressive diseases that can lead to cirrhosis and liver cancer,1 is increasing.2 This is not wholly surprising given that NAFLD/NASH with and without fibrosis are associated with lifestyle (e.g., poor diet and exercise habits) and metabolic risk factors

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (2 weeks ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (2 weeks ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (3 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (4 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (4 weeks ago)